Triple-negative breast cancer is the most difficult to type of breast cancer to treat because it does not respond to hormone therapy. A successful, long-term collaboration between our department of molecular oncology, led by Dave S.B. Hoon, PhD, and the Genome Institute of Singapore, has resulted in one of the most significant breast cancer studies in the last five years. Published in the Journal of Clinical Investigation, one of the highest ranked medical translational journals, the research reports a novel molecular alteration that promotes the aggressive behavior of triple-negative breast cancer. The innovative and translational, molecular breast cancer study findings could lead to the development of novel, targeted therapies to improve the management of patients affected by this disease. Read the full scientific findings in Journal of Clinical Investigation ow.ly/FVyWx
Posted on: Mon, 15 Dec 2014 18:00:10 +0000